• This Project has received funding from the European Union´s Horizon 2020 research and innovation programme under grant agreement No 945118
RESILIENCE helps you survive cancer with a strong heart
  • Home
  • The Project
    Background
    The Resilience Project

    The RESILIENCE project develop a novel healthcare intervention (Remote Ischemic Conditioning, RIC) aimed at reducing the prevalence of chronic heart failure in cancer survivors. 

    More...
    The Challenge
    Reduce the Heart Failure in Cancer Survivors
    According to the WHO, the incidence of cancer is expected to rise by about 70% over the next 20 years.  Half of those diagnosed with cancer will survive for at least a decade, and this survival rate is expected to increase significantly in the future.
    More...
    The Therapy
    Remote Ischemic Conditioning

    Remote ischemic conditioning (RIC) is a phenomenon by which brief, reversible episodes of occlusion and re-occlusion in one organ (e.g. an arm) render remote organs resistant to injury.

    More...
    Partners
    Multidisciplinary consortium
    We count on a multidisciplinary consortium, where different stakeholders of this process are part of the study, from scientists to industry, and from healthcare providers (physicians and nurses) to patients.
    More...
  • Cardiac Magnetic Resonance
    Cardiac Magnetic Resonance

    Cardiac magnetic resonance (CMR) it is a technique without radiation, which is considered the gold-standard for the evaluation of cardiac anatomy, function and even tissue composition. The RESILIENCE trial will use CMR as the main outcome measure methodology, and patients enrolled in the trial will undergo 3 scans across the duration of the study.

    More...
    Vulnerable Heart
    Heart Failure
    Healthy Heart
  • Clinical Trial
    Clinical Trial Synopsis

    Multinational, prospective, proof of concept phase II, double-blinded, sham-controlled, randomized clinical trial (RCT) to evaluate the efficacy and safety of Remote Ischaemic Conditioning (RIC) in Lymphoma patients receiving anthracyclines. Patients scheduled to undergo ≥5 chemotherapy cycles will be eligible.

    More...
  • For patients
    Videos
    closeup-of-support-hands
    More...
    Contact Form
    imgContactForm
    More...
  • Dissemination
    News
    Join us at the European Heart House in Nice for the RESILIENCE multi-stakeholder event: Survive cancer with a strong heart
    September 14 2023
    Science and Innovation Week
    September 11 2023
    RESILIENCE participates in the European Researchers Night in Madrid
    September 8 2023
    RESILIENCE broadens the spectrum of patients who may benefit from entering the trial
    August 14 2023
    Initial visit at the San Carlos Clinical Hospital
    June 16 2023
    More...
    Publications
    Remote Ischemic Conditioning for Anthracycline Cardiotoxicity: The Need to Protect the Most Vulnerable
    July 14 2023
    Remote ischaemic conditioning: defining critical criteria for success—report from the 11th Hatter Cardiovascular Workshop
    August 24 2022
    The Quest for an Early Marker of<br>Anthracycline-Induced Cardiotoxicity
    February 21 2022
    Coronary microcirculation damage in anthracycline cardiotoxicity
    December 23 2021
    Protection from cardiotoxicity of cancer chemotherapy: a novel target for remote ischaemic conditioning?
    December 13 2021
    More...
  • Blog
Twitter Youtube Facebook Linkedin Instagram

Synopsis van klinische proeven

Multinationale, prospectieve, proof of concept fase II, dubbelblinde, schijngecontroleerde, gerandomiseerde klinische studie om de voordelen van ischemische conditionering op afstand te evalueren bij Lymfoompatiënten die antracyclines krijgen.

RESILIENCE is een internationale, prospectieve, proof-of-concept fase II, dubbelblinde, schijngecontroleerde, gerandomiseerde klinische studie (RCT) om de werkzaamheid en veiligheid te evalueren van wekelijkse ischemische conditionering op afstand bij patiënten met Lymfoom die antracyclines krijgen. Patiënten die gepland zijn om verschillende chemotherapiecycli te ondergaan, komen in aanmerking. Patiënten die aan alle inclusie- en geen exclusiecriteria voldoen, zullen worden ingeschreven en drie Cardiac Magnetic Baseline-onderzoeken ondergaan vóór, tijdens en na chemotherapie. Patiënten met een bevestigde LVEF >40% door CMR worden 1:1 gerandomiseerd naar ischemische conditionering op afstand versus gesimuleerde ischemische conditionering op afstand (Sham). Patiënten zullen worden gevolgd voor klinische gebeurtenissen. De mediane follow-up schatting voor klinische eindpunten is 24 maanden.

Samenvatting protocol klinische proef RESILIENCE

Het primaire eindpunt van de studie is de absolute verandering in op CMR gebaseerde linkerventrikelejectiefractie.

Belangrijkste secundaire eindpunten: frequentie van door antracycline geïnduceerde hartschade, frequentie van aritmieën, tijd tot overlijden of ziekenhuisopname voor hartfalen.

Door de patiënt gerapporteerde uitkomst-/ervaringsmaten (PROM’s/PREM’s) zullen gedurende de hele studie worden vastgelegd.

Resilience

Cardiac Magnetic Resonance

  • Cardiac magnetic resonance (CMR) it is a technique without radiation, which is considered the gold-standard for the evaluation of cardiac anatomy, function and even tissue composition.

Clinical Trial Synopsis

  • Multinational, prospective, proof of concept phase II, double-blinded, sham-controlled, randomized clinical trial (RCT) to evaluate the efficacy and safety of Remote Ischaemic PreConditioning.

For patients

Legals

Follow Us

Twitter Youtube Facebook Linkedin Instagram
  • This Project has received funding from the European Union´s Horizon 2020 research and innovation programme under grant agreement No 945118

RESILIENCE is a CNIC project with a multidisciplinary consortium | All Rights Reserved 2022

Logotipo Resilience

Are you a patient participating in RESILIENCE? Here you will find useful information about the details of your participation, activities specifically designed for you. You will also be able to contact RESILIENCE researchers.

In accordance with the provisions of Regulation (EU) 2016/679 on the protection of personal data of natural persons (GDPR), the personal information you have provided will be incorporated into the data processing systems of the Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.) for the purpose of attending your registration application in the restricted area for patients participating in the RESILIENCE study. The legal basis for processing your personal data for this purpose is your explicit consent. Your personal data will not be disclosed to any recipients other than those to whom you authorise or when required by law to do so. You may exercise your rights of access, right to rectification, to object, to erasure, to restriction of processing, data portability and not to be subject to automated individual decision-making. To exercise these rights, as well as to obtain additional information about the processing of your personal data, you can consult the following link Terms and Conditions